BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Ebola outbreak
Hantavirus
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, June 6, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
April 21, 2016
View Archived Issues
Johnson & Johnson profiles activities of first quarter 2016
Read More
First phase I clinical results for IRX-4204 as potential treatment for PD
Read More
Roche reviews pipeline progress of first quarter 2016
Read More
Novel ERK1/2 inhibitor ASN-007 shows strong antitumor activity in multiple RAS mutant models
Read More
Spectrum's Evomela receives 7 years of orphan drug exclusivity
Read More
New model of PMM2-CDG recapitulates human disease in mice
Read More
Bristol-Myers Squibb patents NS5B inhibitors
Read More
FDA removes clinical hold on Cara Therapeutics' CR-845
Read More
N & N Pharmaceuticals begins phase I trial of N-MCT
Read More
AbbVie enters 5-year collaboration agreement with University of Chicago
Read More
Venclexta available in U.S. through Biologics
Read More
AbbVie and Argenx collaborate on anti-GARP antibody candidate ARGX-115
Read More
BioMarin reports phase I/II data on BMN-270
Read More
Eiger licenses PEGylated interferon lambda-1a rights from Bristol-Myers Squibb
Read More
Phase IIb/III study of bimagrumab in sporadic inclusion body myositis misses primary endpoint
Read More
Phase I/II trial explores use of SHR-3680 for metastatic castration-resistant prostate cancer
Read More
Pluristem enters licensing agreement for placental cell therapy patent
Read More
BioMarin updates findings from phase II study of vosoritide in achondroplasia
Read More
Boehringer Ingelheim initiates phase I study of anti-CX3CR1 Nanobody from Ablynx alliance
Read More
Genticel reports additional 12-month data from phase II trial of GTL-001
Read More
Durvalumab plus gefitinib active in NSCLC patients with EGFR mutations
Read More
